全球瞩目的2025 ESMO胃肠道肿瘤大会（ESMO GI Cancers Congress 2025）将于7月2~5日在西班牙巴塞罗那隆重举行，同步线上直播。本届学术盛会将汇聚全球顶尖专家和研究者，共同致力于推动消化道肿瘤治疗的发展。大会将聚焦分子预防、诊断、精准治疗等广泛议题，通过演讲、争议性议题探讨等形式，深入剖析最新研究成果、创新治疗策略和有望重塑胃肠道肿瘤治疗未来的新兴技术。【肿瘤资讯】特此整理了本届大会中入选Proffered Paper session（优选口头报告）（6项）和Mini Oral session（迷你口头报告）（15项）的重磅研究，为诸君呈现消化道肿瘤领域的前沿进展。
优选口头报告（Proffered Paper Session）
1O - Nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): health-related quality of life (HRQoL) analyses from CheckMate 8HW
中文标题：纳武利尤单抗（NIVO）联合伊匹木单抗（IPI）对比NIVO单药治疗微卫星高度不稳定/错配修复缺陷（MSI-H/dMMR）转移性结直肠癌（mCRC）：来自CheckMate 8HW研究的健康相关生活质量（HRQoL）分析
讲者：Elena Elez Fernandez (西班牙，巴塞罗那)
2O - Clinical utility of including circulating tumor DNA (ctDNA) monitoring in standard of care (SoC) colorectal cancer (CRC) surveillance
中文标题：循环肿瘤DNA（ctDNA）监测纳入结直肠癌（CRC）标准治疗随访中的临床应用价值
讲者：N. Arvind Dasari (美国，休斯顿)
3O - Association of ctDNA Clearance with Disease-Free Survival, Safety, and Quality of Life from ctDNA-Directed Therapy: Findings from the ALTAIR Study
中文标题：ctDNA清除与无病生存期（DFS）、安全性和生活质量的相关性：来自ALTAIR研究的结果
讲者：Masahito Kotaka (日本，神户)
4O - Liquid biopsy-guided selection for anti-EGFR re-treatment in RAS/BRAF wild-type (wt) chemorefractory metastatic colorectal cancer patients (mCRC pts): Results from the phase II randomized PARERE trial
中文标题：基于液体活检的抗EGFR再治疗方案选择：针对RAS/BRAF野生型化疗难治性转移性结直肠癌患者的研究结果——来自II期随机PARERE试验
讲者：Paolo Ciracì (意大利)
5O - A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies
中文标题：一项评估BRAF抑制剂治疗抗EGFR疗法引起的痤疮样皮疹疗效的双盲、安慰剂对照、随机II期临床试验
讲者：Ofer Purim (以色列)
148O - Overall evaluation of health-related quality of life (HRQoL) and efficacy assessment in patients (pts) who discontinued (d/c) due to treatment-related adverse events (TRAEs): results from CheckMate 9DW
中文标题：因治疗相关不良事件（TRAEs）中断治疗的患者的健康相关生活质量 (HRQoL）和疗效的总体评估：来自CheckMate 9DW研究的结果
讲者：Bruno Sangro (西班牙)
迷你口头报告（Mini Oral session）
6MO - Rechallenge with amivantamab, an EGFR-MET bispecific antibody, after disease progression on prior EGFR inhibitor in left-sided RAS/BRAF wild-type metastatic colorectal cancer: Updated results from OrigAMI-1
中文标题：在左半RAS/BRAF野生型转移性结直肠癌患者中，既往EGFR抑制剂治疗进展后使用EGFR-MET双特异性抗体amivantamab再挑战：OrigAMI-1研究的更新结果
讲者：Dirk Arnold (德国，汉堡)
7MO - Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): final results of the randomised phase II PANIRINOX-UCGI28 study
中文标题：帕尼单抗+FOLFIRINOX或mFOLFOX6方案治疗经循环DNA检测为RAS/BRAF野生型不可切除转移性结直肠癌患者：随机II期PANIRINOX-UCGI28研究的最终结果
讲者：Thibault Mazard (法国)
149MO - Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 Study
中文标题：Irpagratinib（ABSK-011）联合阿替利珠单抗用于一线及既往接受过免疫检查点抑制剂（ICIs）治疗的FGF19过表达（+）晚期肝细胞癌（HCC）患者：II期ABSK-011-201研究的更新结果
讲者：Qi Cheng (华中科技大学同济医学院附属同济医院)
150MO - Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis
中文标题：度伐利尤单抗和替西木单抗一线治疗预后不良的肝细胞癌（HCC）患者：IIIb期SIERRA研究的安全性结果
讲者：Stephen L. Chan (香港特别行政区)
222MO - Tumor immune microenvironment and survival outcome following preoperative chemoradiotherapy in locally advanced rectal cancer: results from the STAR-01 study cohort
中文标题：局部晚期直肠癌术前放化疗后肿瘤免疫微环境与生存结局的关系：来自STAR-01研究队列的结果
讲者：Francesca Negri (意大利)
223MO - Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): the ShorTrip study
中文标题：短程放疗（SCRT）后联合FOLFOXIRI方案巩固化疗作为全程新辅助治疗（TNT）用于局部晚期直肠癌患者的II期研究：ShorTrip研究
讲者：Beatrice Borelli (意大利)
260MO - AGITG ASCEND study: Randomised, double-blind phase II study of certepetide (CERT) or placebo (PLA) added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)—Cohort B progression free survival (PFS) results.
中文标题：Certepetide（CERT）或安慰剂联合吉西他滨+白蛋白紫杉醇用于未经治疗的转移性胰腺导管腺癌（mPDAC）患者的随机、双盲II期研究——AGITG ASCEND研究队列B的无进展生存期（PFS）结果
讲者：Andrew Dean (澳大利亚)
261MO - A Phase II Study of Olaparib in patients (pts) with Advanced Biliary Tract Cancer (aBTC) with aberrant homologous recombinant repair (HRR) mutations
中文标题：奥拉帕利治疗伴有同源重组修复（HRR）突变的晚期胆道癌（aBTC）患者的II期研究
讲者：Daniel Ahn (美国)
262MO - Preliminary efficacy outcomes of ivosidenib in patients with IDH1 mutated cholangiocarcinoma (mIDH1 CCA): initial results from the phase 3b ProvIDHe study
中文标题：Ivosidenib治疗IDH1突变胆管癌（mIDH1 CCA）患者的初步疗效结果：来自IIIb期ProvIDHe研究的初步结果
讲者：John A. Bridgewater (英国，伦敦)
388MO - Preliminary Safety and Efficacy of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Combination with Nivolumab and mFOLFOX in Metastatic Gastroesophageal Carcinoma (mGEC)
中文标题：Givastomig（一种新型Claudin 18.2/4-1BB双特异性抗体）联合纳武利尤单抗和mFOLFOX方案治疗转移性胃食管癌 (mGEC）的初步安全性和有效性
讲者：Samuel J. Klempner (美国，波士顿)
389MO - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis
中文标题：替雷利珠单抗+化疗对比安慰剂+化疗用于局部晚期食管鳞状细胞癌（ESCC）患者：RATIONALE-306研究的亚组分析
讲者：Eric Van Cutsem (比利时)
390MO - Definitive Chemoradiotherapy for Adenocarcinoma of the Esophagus: a Dutch Population-Based Cohort
中文标题：食管腺癌的根治性放化疗：一项基于荷兰人群的队列研究
讲者：Sanjiv Gangaram-Panday (荷兰，鹿特丹)
391MO - Phase III randomized IRIGA trial of FOLFIRINOX versus mFOLFOX6 as first-line treatment for patients with HER2-negative gastric and gastroesophageal adenocarcinoma
中文标题：FOLFIRINOX对比mFOLFOX6作为HER2阴性胃和胃食管腺癌患者一线治疗的III期随机IRIGA试验
讲者：Daria Gavrilova (俄罗斯)
392MO - Recurrent Patient-Reported Outcome (PRO)-Based Deterioration Predicts Overall Survival (OS) in Patients with Advanced Gastric Adenocarcinoma with PD-L1 Score of ≥5%: Results from the RATIONALE-305 Trial
中文标题：基于患者报告结局（PRO）的恶化情况可预测PD-L1评分≥5%的晚期胃腺癌患者的总生存期（OS）：来自RATIONALE-305试验的结果
讲者：Markus Moehler (德国)
393MO - Overall survival in germline CDH1 pathogenic variant (PV) carriers: A Multicenter Comparative Analysis Study
中文标题：胚系CDH1致病性变异携带者的OS：一项多中心比较分析研究
讲者：Mara Cruellas Lapena (西班牙，巴塞罗那)
排版编辑：肿瘤资讯-Marie
苏公网安备32059002004080号
